US medical devices industry saw a drop of 7.84% in overall deal activity during January 2022, when compared with the last 12-month average, led by Owens & Minor’s $1.6bn acquisition of Apria, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 94 deals worth $4.7bn were announced in January 2022, compared with the 12-month average of 102 deals.
venture financing was the leading category in the month in terms of volume with 54 deals, which accounted for 57.5% of all deals.
In second place was M&A with 31 deals, followed by private equity with nine transactions, respectively accounting for 33% and 9.6% of overall deal activity in the US technology industry during the month.
In terms of value of deals, M&A was the leading deal category in the US medical devices industry with total deals worth $3.26bn, while venture financing and private equity deals totalled $1.17bn and $250m respectively.
US medical devices industry deals in January 2022: Top deals
The top five medical devices industry deals accounted for 67.7% of the overall value during January 2022.
The combined value of the top five medical devices deals stood at $3.16bn, against the overall value of $4.7bn recorded for the month.
The top five medical devices industry deals of January 2022 tracked by GlobalData were:
1) Owens & Minor $1.6bn acquisition deal with Apria
2) The $623m acquisition of GeneDX by Sema4 OpCo
3) ConvaTec Group $450m acquisition deal with Triad Life Sciences
4) The $250m private equity of Fluidigm by Casdin Capital and Viking Global Investors
5) Maravai LifeSciences Holdings $240m acquisition deal with MyChem
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.